SCHEMBL16710028

SCHEMBL16710028

COc1ccc(CN(Cc2ccc3c(c2)OCO3)Cc2nc(C(=O)NO)cs2)c(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.46
MAPT P10636 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
KMT2A Q03164 5/20 0.45
MEN1 O00255 2/20 0.43
TP53 P04637 1/20 0.43
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
PKM P14618 1/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
BMP1 P13497 2/20 0.41
POLB P06746 2/20 0.41
LMNA P02545 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HSD17B10 Q99714 2/20 0.41
TSHR P16473 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16710120 0.91 MMP13 (0.47) KDM4EMAPTSMN1; SMN2KMT2AMEN1
SCHEMBL16706662 0.91 SMN1; SMN2 (0.45) KDM4EMAPTSMN1; SMN2KMT2AMEN1
SCHEMBL16706755 0.90 SMN1; SMN2 (0.43) KDM4EMAPTSMN1; SMN2KMT2AMEN1
SCHEMBL16710112 0.90 MAPT (0.43) KDM4EMAPTSMN1; SMN2KMT2AMEN1
SCHEMBL16710113 0.89 RAB9A (0.44) KDM4EMAPTSMN1; SMN2KMT2AMEN1
SCHEMBL16706756 0.89 KMT2A (0.44) KDM4EMAPTSMN1; SMN2KMT2AMEN1
SCHEMBL16706810 0.89 KMT2A (0.43) KDM4EMAPTSMN1; SMN2KMT2AMEN1
SCHEMBL16710038 0.89 LMNA (0.46) KDM4EMAPTSMN1; SMN2KMT2AMEN1
SCHEMBL16706684 0.88 KDM4E (0.42) KDM4EMAPTSMN1; SMN2KMT2AMEN1
SCHEMBL16710108 0.88 HTR2A (0.46) MAPTSMN1; SMN2KMT2AMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951033-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2018-04-24 US disclosed
US-20170158657-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2017-06-08 US disclosed
US-9556111-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2017-01-31 US disclosed
US-20150133510-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2015-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158657-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS TNNI3, TNNT2, MYLK2 KDM4E 1986/4885MAPT 1807/4885SMN1; SMN2 2862/4885
US-20150133510-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS TNNI3, TNNT2, MYLK2 KDM4E 2399/4885MAPT 1886/4885SMN1; SMN2 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.